- Home
- CTRN vs NMRA Comparison
CTRN vs NMRA Comparison
Compare CTRN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTRN | NMRA |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.2M | 424.4M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CTRN | NMRA |
|---|---|---|
| Price | $45.40 | $2.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $52.00 | $8.00 |
| AVG Volume (30 Days) | 97.7K | ★ 2.1M |
| Earning Date | 03-17-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,741,000.00 | N/A |
| Revenue This Year | $10.69 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.77 | N/A |
| 52 Week Low | $16.82 | $0.61 |
| 52 Week High | $49.50 | $3.25 |
Technical Indicators
Market Signals| Indicator | CTRN | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 48.78 |
| Support Level | $41.44 | $1.95 |
| Resistance Level | $44.43 | $2.11 |
| Average True Range (ATR) | 2.09 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 57.73 | 47.22 |
Price Performance
Historical ComparisonAbout CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.